BioNTech Shares Down 3.4%; Sees 2024 Revenue Below Wall Street Views
10 January 2024 - 6:57AM
Dow Jones News
By Josh Beckerman
BioNTech shares were down 3.4% after the company projected 2024
revenue of about 3 billion euros ($3.28 billion), compared with the
average estimate of $4.11 billion from analysts polled by
FactSet.
The stock was recently at $108.04 and is down about 29% over the
past 52 weeks.
The immunotherapy company expects topline growth in 2025.
BioNTech, widely known for its Covid-19 vaccine, has been
expanding in areas including oncology. The company said Tuesday
that "late-stage trials are ongoing in multiple oncology
indications, and we plan to have ten or more potentially
registrational trials in our pipeline by the end of 2024."
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
January 09, 2024 14:42 ET (19:42 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
BioNTech (NASDAQ:BNTX)
Historical Stock Chart
From Apr 2024 to May 2024
BioNTech (NASDAQ:BNTX)
Historical Stock Chart
From May 2023 to May 2024